Kevin Judice, DICE Therapeutics CEO
Now with positive PhI data, DICE goes after public offering in search of $250M
First the positive data, then the public offering. Akin to a host of other biotechs seeking to refill their coffers on the heels of an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
